Regeneron (REGN) Gets Positive CHMP Opinion for Lymphoma Drug

Regeneron Pharmaceuticals, Inc. (REGN) announced that the European Medicines Agency’s (“EMA”) Committee for Medicinal Products for Human Use (“CHMP”) has recommended approval of oncology candidate odronextamab.The CHMP adopted a positive opinion recommending conditional marketing authorization of odronextamab to treat adults with relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy.A final decision from the European Comm ...